What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrea Palicelli, Martina Bonacini, Stefania Croci, Cristina Magi-Galluzzi, Sofia Cañete-Portillo, Alcides Chaux, Alessandra Bisagni, Eleonora Zanetti, Dario De Biase, Beatrice Melli, Francesca Sanguedolce, Magda Zanelli, Maria Paola Bonasoni, Loredana De Marco, Alessandra Soriano, Stefano Ascani, Maurizio Zizzo, Carolina Castro Ruiz, Antonio De Leo, Guido Giordano, Matteo Landriscina, Giuseppe Carrieri, Luigi Cormio, Daniel M. Berney, Jatin Gandhi, Giacomo Santandrea, Maria Carolina Gelli, Alessandro Tafuni, Moira Ragazzi
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:49bdba14c7fc4b88b941d1f188ef305f
record_format	dspace
spelling	oai:doaj.org-article:49bdba14c7fc4b88b941d1f188ef305f2021-11-25T17:12:11ZWhat Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations10.3390/cells101131652073-4409https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f2021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/3165https://doaj.org/toc/2073-4409Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.Andrea PalicelliMartina BonaciniStefania CrociCristina Magi-GalluzziSofia Cañete-PortilloAlcides ChauxAlessandra BisagniEleonora ZanettiDario De BiaseBeatrice MelliFrancesca SanguedolceMagda ZanelliMaria Paola BonasoniLoredana De MarcoAlessandra SorianoStefano AscaniMaurizio ZizzoCarolina Castro RuizAntonio De LeoGuido GiordanoMatteo LandriscinaGiuseppe CarrieriLuigi CormioDaniel M. BerneyJatin GandhiGiacomo SantandreaMaria Carolina GelliAlessandro TafuniMoira RagazziMDPI AGarticlePD-L1prostatecanceradenocarcinomaimmunohistochemistrytarget-therapyBiology (General)QH301-705.5ENCells, Vol 10, Iss 3165, p 3165 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Biology (General) QH301-705.5
spellingShingle	PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Biology (General) QH301-705.5 Andrea Palicelli Martina Bonacini Stefania Croci Cristina Magi-Galluzzi Sofia Cañete-Portillo Alcides Chaux Alessandra Bisagni Eleonora Zanetti Dario De Biase Beatrice Melli Francesca Sanguedolce Magda Zanelli Maria Paola Bonasoni Loredana De Marco Alessandra Soriano Stefano Ascani Maurizio Zizzo Carolina Castro Ruiz Antonio De Leo Guido Giordano Matteo Landriscina Giuseppe Carrieri Luigi Cormio Daniel M. Berney Jatin Gandhi Giacomo Santandrea Maria Carolina Gelli Alessandro Tafuni Moira Ragazzi What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
description	Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.
format	article
author	Andrea Palicelli Martina Bonacini Stefania Croci Cristina Magi-Galluzzi Sofia Cañete-Portillo Alcides Chaux Alessandra Bisagni Eleonora Zanetti Dario De Biase Beatrice Melli Francesca Sanguedolce Magda Zanelli Maria Paola Bonasoni Loredana De Marco Alessandra Soriano Stefano Ascani Maurizio Zizzo Carolina Castro Ruiz Antonio De Leo Guido Giordano Matteo Landriscina Giuseppe Carrieri Luigi Cormio Daniel M. Berney Jatin Gandhi Giacomo Santandrea Maria Carolina Gelli Alessandro Tafuni Moira Ragazzi
author_facet	Andrea Palicelli Martina Bonacini Stefania Croci Cristina Magi-Galluzzi Sofia Cañete-Portillo Alcides Chaux Alessandra Bisagni Eleonora Zanetti Dario De Biase Beatrice Melli Francesca Sanguedolce Magda Zanelli Maria Paola Bonasoni Loredana De Marco Alessandra Soriano Stefano Ascani Maurizio Zizzo Carolina Castro Ruiz Antonio De Leo Guido Giordano Matteo Landriscina Giuseppe Carrieri Luigi Cormio Daniel M. Berney Jatin Gandhi Giacomo Santandrea Maria Carolina Gelli Alessandro Tafuni Moira Ragazzi
author_sort	Andrea Palicelli
title	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
title_short	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
title_full	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
title_fullStr	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
title_full_unstemmed	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
title_sort	what do we have to know about pd-l1 expression in prostate cancer? a systematic literature review. part 2: clinic–pathologic correlations
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f
work_keys_str_mv	AT andreapalicelli whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT martinabonacini whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT stefaniacroci whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT cristinamagigalluzzi whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT sofiacaneteportillo whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT alcideschaux whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT alessandrabisagni whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT eleonorazanetti whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT dariodebiase whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT beatricemelli whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT francescasanguedolce whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT magdazanelli whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT mariapaolabonasoni whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT loredanademarco whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT alessandrasoriano whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT stefanoascani whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT mauriziozizzo whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT carolinacastroruiz whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT antoniodeleo whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT guidogiordano whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT matteolandriscina whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT giuseppecarrieri whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT luigicormio whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT danielmberney whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT jatingandhi whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT giacomosantandrea whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT mariacarolinagelli whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT alessandrotafuni whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations AT moiraragazzi whatdowehavetoknowaboutpdl1expressioninprostatecancerasystematicliteraturereviewpart2clinicpathologiccorrelations
_version_	1718412645749489664

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

Ejemplares similares